Tirzepatide 30mg
Tirzepatide is a first-in-class dual GIP (Glucose-dependent Insulinotropic Polypeptide)/GLP-1 receptor co-agonist — a single peptide that activates both incretin hormone receptors simultaneously. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity management, it represents the next generation of incretin-based therapeutics.
Research has characterized tirzepatide's superior glycemic control and weight reduction compared to GLP-1 mono-agonists, through additive effects on insulin secretion, glucagon suppression, gastric emptying, and hypothalamic appetite circuits. The GIP component also appears to contribute to adipose tissue remodeling.
Specifications: 30mg lyophilized powder | Purity ≥99% (HPLC) | MW 4813.5 g/mol | Store at −20°C
For Research Use Only. Not for human or veterinary use. This product is intended solely for in vitro and laboratory research. Not approved by the FDA. Not a drug, food, or cosmetic. Keep out of reach of children.
